PTHS PTHS
Company Profile ↓Company Overview
PTHS (PTHS) is a publicly traded company listed on with a market capitalization of $92.31M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +35.90% |
| 6 Months: | +22.17% |
| 3 Months: | +12.14% |
| 1 Month: | +16.02% |
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)54.91 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 0 | 0 | 7.41M | 9.39M | 10.91M |
| Cost of Revenue | - | - | - | - | - | - | - | 0 | - | 4.97M | 4.39M | 5.31M |
| Gross Profit | - | - | - | - | - | - | - | 0 | - | 2.43M | 5.00M | 5.59M |
| Operating Expenses | - | - | - | - | - | - | - | 1.83M | 3.23M | 17.79M | 17.00M | 18.68M |
| Operating Income | -914.58K | -777.16K | -1.29M | -1.93M | -1.76M | -2.05M | - | -1.83M | -3.23M | -15.36M | -12.00M | -13.09M |
| EBITDA | - | - | - | - | - | - | - | -1.83M | -3.23M | -14.68M | -26.05M | -6.38M |
| Interest Expense | - | - | - | - | - | - | - | 134.00K | 218.52K | 1.35M | 1.31M | 2.35M |
| Pretax Income | - | - | - | - | - | - | - | -1.97M | -3.45M | -16.70M | -28.59M | -10.24M |
| Tax Provision | - | - | - | - | - | - | - | 0 | 0 | -465.00K | -6.92M | 0 |
| Net Income | -966.56K | -953.35K | -1.42M | -2.56M | -1.77M | -1.70M | - | -1.97M | -3.45M | -16.24M | -21.66M | -10.24M |
| Diluted EPS | - | - | - | -0.55 | -3.07 | -2.93 | - | -3.21 | -5.38 | -5.30 | -6.87 | -3.09 |
| R&D Expense | 186.12K | 49.95K | 49.13K | 466.61K | 12.96K | 415.00K | - | 194.00K | 514.81K | 145.00K | - | 186.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 16.80M |
| Cost of Revenue | - | - | - | 0 | 9.37M |
| Gross Profit | - | - | - | 0 | 7.43M |
| Operating Expenses | - | 2.32M | 6.86M | 7.57M | 39.86M |
| Operating Income | - | -2.32M | -6.86M | -7.57M | -32.43M |
| EBITDA | - | -2.32M | -6.86M | -7.17M | -45.41M |
| Interest Expense | - | 140.43K | 518.51K | 786.00K | 3.01M |
| Pretax Income | - | -2.46M | -7.38M | -7.96M | -50.71M |
| Tax Provision | - | 0 | 0 | 0 | -7.39M |
| Net Income | - | -2.46M | -7.38M | -7.96M | -43.32M |
| Diluted EPS | - | -2.65 | -12.80 | -14.27 | -23.04 |
| R&D Expense | - | 391.73K | 2.58M | 1.18M | 1.23M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 55.07K | 96.39K | 1.37M | 130.40M |
| Current Assets | - | 55.07K | 96.39K | 1.37M | 53.41M |
| Cash & Equivalents | - | 55.07K | 96.39K | 513.00K | 17.97M |
| Inventory | - | - | - | 0 | 23.57M |
| Receivables | - | - | - | 0 | 8.86M |
| Total Liabilities | - | 3.76M | 6.54M | 4.08M | 91.52M |
| Current Liabilities | - | 3.76M | 6.54M | 4.08M | 25.99M |
| Long Term Debt | - | - | - | - | 31.44M |
| Total Debt | - | 540.43K | 1.27M | 2.19M | 34.83M |
| Total Equity | - | -3.71M | -6.44M | -2.71M | 38.88M |
| Shares Outstanding | - | 576.75K | 576.75K | 610.38K | 3.23M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -1.57M | -981.03K | -5.79M | -22.59M |
| Investing Cash Flow | - | - | - | 0 | -5.24M |
| Financing Cash Flow | - | 1.62M | 1.02M | 6.21M | 45.34M |
| Capital Expenditure | - | - | - | - | -8.00M |
| Free Cash Flow | - | -1.57M | -981.03K | -5.79M | -30.59M |
| Net Change in Cash | - | 55.07K | 41.32K | 417.00K | 17.51M |
| Share Buybacks | - | - | - | 75.00K | 0 |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 44.2% |
| Operating Margin % | - | - | - | - | -193.1% |
| Net Margin % | - | - | - | - | -257.9% |
| ROE % | - | 66.3% | 114.5% | 293.1% | -111.4% |
| ROCE % | - | 62.5% | 106.5% | 279.0% | -31.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PTHS
Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026
Company to hold a conference call at 8:30 a.m. ETDURHAM, N.C., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for u…
Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders
DURHAM, N.C., July 24, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS) (the “Company” or “Pelthos”) today announced that it will hold its 2026 Annual Meeting of Stockholders virtually on Tuesday, September 29, 2026 …
Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes
DURHAM, N.C., June 30, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, (“Pelthos”), today announced …
Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
DURHAM, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, (“Pelthos”), today announced t…
Pelthos Therapeutics Inc. Q1 2026 Earnings Call Summary
Moby summary of Pelthos Therapeutics Inc.'s Q1 2026 earnings call
Pelthos Therapeutics Inc (PTHS) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...
Pelthos Therapeutics Inc (PTHS) reports significant revenue growth and sales force expansion, despite facing a net loss and rising expenses in Q1 2026.
PTHS — Frequently Asked Questions
What is the current share price of PTHS?
As of 2026-08-05 17:25 PDT, PTHS trades at $28.54 on NASDAQ/NYSE. Its 52-week range is $18.18 to $37.42.
What is the market capitalisation of PTHS?
PTHS has a market capitalisation of $92.31M on NASDAQ/NYSE.
What is the P/E ratio of PTHS?
PTHS trades at a trailing price-to-earnings (P/E) ratio of -1.24. Its price-to-book (P/B) ratio is 2.37.
What is the return on equity (ROE) of PTHS?
PTHS has a return on equity (ROE) of -111.41%. Its return on capital employed (ROCE) is -31.06%.
Is PTHS a good stock to buy?
This page provides a data-driven analysis of PTHS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.